RxDoctor Payments Data

Deborah Lindahl, NP

Nurse Practitioner · Brunswick, GANPI 1114223690

Payments from drug & device makers

$4,530in general payments, 2019–2025

Across 245 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$396
  • Takeda Pharmaceuticals U.S.A., Inc.$309
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$277
  • Ironwood Pharmaceuticals, Inc$196
  • QOL Medical, LLC$124
  • plus $955 from 20 others

What the payments were for

  • Food & beverage$4,530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,530 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$34,920
Medicare patients
300
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab20$531,214
Humira(Cf) PenAdalimumab25$330,829
EntyvioVedolizumab23$201,478
LinzessLinaclotide158$165,399
RemicadeInfliximab11$164,901
XifaxanRifaximin29$100,973
Cimzia (2 Pack)Certolizumab Pegol12$69,957
CreonLipase/Protease/Amylase13$39,826
ViberziEluxadoline11$17,711
Mesalamine39$14,022
TrulancePlecanatide17$13,106
Dexlansoprazole DrDexlansoprazole17$6,121
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C40$5,516
Ursodiol34$5,251
Lansoprazole21$4,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$396$696,11531 claims
AbbVieLinzess, Creon, Viberzi$2,273$222,935182 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$309$201,47823 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$277$119,59586 claims
Braintree Laboratories, Inc.Suflave$33$1,49912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →